Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.
Circulating endothelial cells (CECs) were evaluated by flow cytometry in immunodeficient mice bearing human lymphoma. A trend toward higher CEC values was observed on days 7 and 14 after transplant, and differences versus controls were highly significant on day 21 (P = 0.0061). A strong correlation was found between CEC and tumor volume (r, 0.942; P = 0.004) and between CEC and tumor-generated VEGF (r, 0.669; P = 0.02). In mice given cyclophosphamide, most of the circulating apoptotic cells were hematopoietic and not endothelial. Conversely, in mice given endostatin, all of the increase in apoptotic cells was in the endothelial cell compartment. CEC evaluation is promising as a noninvasive, surrogate angiogenesis marker.
Monestiroli
S
S
Division of Hematology-Oncology, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
Mancuso
P
P
Burlini
A
A
Pruneri
G
G
Dell'Agnola
C
C
Gobbi
A
A
Martinelli
G
G
Bertolini
F
F
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D002051:Burkitt Lymphoma / Q000097:blood* / Q000473:pathology*; D002453:Cell Cycle; D002470:Cell Survival; D003094:Collagen / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D004195:Disease Models, Animal; D043169:Endostatins; D004730:Endothelium, Vascular / Q000473:pathology*; D005434:Flow Cytometry; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000188:drug therapy / Q000473:pathology*; D010446:Peptide Fragments / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D003520:Cyclophosphamide; D003094:Collagen